Triparna Sen: Bridging Preclinical Discovery and Clinical Impact
Triparna Sen, Professor in the Department of Internal Medicine, Associate Director of Research, and Director of the Lung Cancer Preclinical Therapeutic Platform at The Ohio State University, shared a post on X:
“I am honored and thrilled to share that, starting August 1, I have joined The Ohio State University as a Professor in the Department of Internal Medicine, Associate Director of Research, and Director of the Lung Cancer Preclinical Therapeutic Platform in the Division of Medical Oncology.
The transition to this leadership role is both humbling and exciting. I will lead efforts to advance translational research across all solid tumors, with a mission to bridge preclinical discovery and clinical impact.
I am excited to begin the next chapter of the Sen Lab here at The Ohio State University Wexner Medical Center, where my lab will continue to focus on resistance mechanisms, lineage plasticity, and therapeutic innovation in aggressive thoracic cancers. I look forward to building a strong, collaborative lung cancer research program.
I am deeply grateful to my mentors and colleagues at Icahn School of Medicine at Mount Sinai who have shaped my journey, and I look forward to working with the exceptional community at Ohio State Medical Oncology as we push the boundaries of cancer research together.”
More posts featuring Triparna Sen on OncoDaily.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023